Corus News

In the spotlight; Dentaal Tema, high end laboratory in Bruges

Bruges, Belgium

Corus´ Dentaal Tema laboratory, located in Bruges, has a brand new venue!

Corporate 24 July, 2023

Dentalaxe Joins Forces with Corus

Amiens, France

We are thrilled to announce that Dentalaxe, a French laboratory specializing in dental prosthetics, located in Amiens, has joined the Corus lab group.

Corus Will be present at SOCE Zaragoza 2023

Zaragoza, Spain

One more year, Corus will be present at the IX Annual Congress of the Spanish Society of Digital Dentistry and New Technologies (SOCE) that will take place on 28 and 29 April, at the Palacio de Congresos de Zaragoza.

Nicolas Bonnard and Jeroen van Asten interviewed at the Dental Tribune’s IDS 2023 especial edition

On the occasion of the special edition for IDS, the leading trade fair for the dental industry in Europe, The Dental Tribune interviewed our CEOs, Nicolas Bonnard and Jeroen van Asten.

Corus will be present at IDS 2023


From 14 to 18 March 2023, the leading trade fair for the dental industry, which takes place every two years in Germany, returns to Cologne.

Corus expands into the UK with the integration of Byrnes Dental Laboratory


We are very excited to announce that our galaxy is expanding once again! Corus has integrated Byrnes Dental Laboratory, UK’s market reference in digital dental prothesis.

Corus expands into Scandinavia with the integration of Nordentic, the region’s largest player in dental technology.

Scandinavia, Denmark, Sweden, Norway

The integration will see the company offering its products and services in Spain, France, the Netherlands, Belgium, Sweden, Norway, Denmark and Portugal through 63 laboratories and more than 1,500 employees.

Last entry in the blog

A project co-funded by Corus finds a new therapeutic alternative for HER2+ breast cancer

In October, with Nobrux, we donated €10,000 to help co-fund the project ‘New HER2+ Breast Cancer Therapies’ led by Dr Gema Moreno (Science Foundation of the Spanish Breast Cancer Association). And the study got results! A discovery was made that has opened the doors to a new therapeutic alternative for patients with HER2+ breast cancer, an alternative that can also be applied to other HER2+ tumours.

Contact form